Therapy Finder

Early stage lung cancer is localized around the site of origin where as advanced lung cancer has spread to lymph nodes and possibly other tissues. This tool helps doctors and patients identify potential treatments for patients with advanced lung cancer.

Histology is determined by viewing a biopsy sample under a microscope - this information can be found in the pathology report. Distinct histologies are often associated with different prognoses and treatment options.

For advanced lung cancer: these are secondary sites that lung cancer has spread to from its primary origin. Information about the size and location of metastasis can impact choice of treatments. For example, active brain metastases often disqualify patients from participating in clinical trials.

Genetic mutations can contribute to lung cancer growth. This tool uses mutational status to help identify potentially relevant therapies.

The EGFR gene if often aberrant in adenocarcinomas and sometimes in squamous and large cell carcinoma.

The KRAS gene is commonly mutated in lung adenocarcinomas.

EML4-ALK is a fusion oncogene that occurs in a small percentage of lung adenocarcinomas.

VeriStrat is a blood test that predicts responsiveness to certain drugs such as EGFR inhibitors.

Several drugs that target these aberrations are approved and some are in clinical trials for lung cancer.